银杏提取物对急性冠脉综合征介入治疗后患者血小板活化因子的影响

The effect of Ginkgo biloba extract on platelet activating factor and inflammatory factors in patients with acute coronary syndrome after percutaneous coronary intervention

目的探讨银杏提取物对急性冠脉综合征(ACS)介入治疗后患者血小板活化因子(PAF)的影响。方法2015年6月至2016年8月行择期经皮冠状动脉介入(PCI)治疗的ACS患者40例,术后随机分为观察组和对照组,每组20例。两组均于PCI术后常规双联抗血小板以及他汀调脂治疗。观察组加用天保宁(银杏叶提取物,19.2mg/片,36片/盒)1片/次,3次/d口服。术前、术后24h,术后2周检测PAF水平、超敏C反应蛋白(hs-CRP)和血小板聚集率。术前及术后2周进行心脏超声检查,术后2周观察主要心血管不良事件(MACE)。结果两组患者PCI术后24h的PAF水平,hs-CRP,血小板聚集率均较PCI术前升高,差异均有统计学意义(均P<0.05)。PCI术后2周,观察组PAF水平、hs-CRP[(1667.46±390.98)p g/ml、(4.34±2.01)mg/L]均低于对照组[(1823.46±434.76)p g/ml、(7.09±4.78)mg/L],差异有统计学意义(均P<0.05)。PCI术后2周,观察组LVEF值与对照组及自身术前比较,差异有统计学意义(P<0.05),心绞痛发作观察组显著低于对照组(P<0.05)。结论银杏提取物可降低PCI术后PAF与hs-CRP表达,同时减少临床心绞痛的发生。

Objective To explore the effect of Ginkgo biloba extract on platelet activating factor （PAF）in patients withacute coronary syndrome（ACS）after percutaneous coronary intervention（PCI） . Methods 40 ACS patients underwentPCI and then were randomly divided into observation group（n=20） and control group（n=20） . Tianbaoning pill （Ginkgobiloba extract,19.2 mg three times per day）was added to observation group based on routine double antiplatelet andstatin therapy for both groups. PAF,hs-CRP and platelet aggregation rate were measured before PCI, 24hours and twoweeks after PCI. Echocardiography was performed before and 2 weeks after PCI. The main adverse cardiac events wererecorded during2 weeks after PCI. Results PAF,hs-CRP and platelet aggregation rate were significantly higher 24hafter than before PCI in both groups（P〈0.05 for all） . PAF and hs-CRP were significantly lower in observation group[ （1667.46±390.98） pg/ml,（4.34±2.01） mg/L] than control group[ （1823.46±434.76） pg/ml,（7.09±4.78） mg/L] 2 weeksafter PCI. LVEF improved significantly in 2 weeks after PCI in observation group and higher than control group（P〈0.05） .Angina pectoris occurred significantly less in observation group than control group after PCI. Conclusion Ginkgo bilobaextract can inhibit the expression of platelet activating factor and hs-CRP and improve angina pectoris.